[1] Vollenweidera F.X., Leendersb K.L., Oyec I., Hella D., Angsta J. (1997)  Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). EurNeuropsychopharm (7): 25–38.

[2] Allen A., Robles J., Dovenski and Wm., Calderon S. (2004); PCP: A review of synthetic methods for forensic clandestine investigation. Forensic Science International(61): 2-3, 85-100.

[3] –



[6]- Jansen K.L. (2000); A review of the nonmedical use of ketamine: use, users and consequences. JPsychoactive Drugs; Oct-Dec; 32(4):419-33.







[13] – Epidemiologic Trends in Drug Abuse; Vol. 1 Highlights and Executive Summary; June 2001.

[14] Kamiyama H., Matsumoto M., Otani S., Kimura S.I., Shimamura K.I., Ishikawa S., Yanagawa Y., Togashi H. (2011); Mechanisms underlying ketamine-induced synaptic depression in rat hippocampus-medial.  Neuroscience, 17; 177:159-69.


[16] ketamina – Uma nova leitura Prof. Doutor João Batista Santos Garcia, prática hospitalar Ano IX nº53, Setembro/Outubro 2007


[18] Lorrain D.S., Baccei C.S., Bristow L.J., Anderson J.J., Varney M.A. (2002); Effects of ketamine and n-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuropharmacology, Merck Research Laboratories, Avera Pharmaceuticals.

[19] Legranda T, Royb S, Monchauda C, Grondina C, Duval M, Jacqz-Aigraina E. (2008); Determination of ketamine and norketamine in plasma by micro-liquid chromatography–mass spectrometry. J Pharmaceut Biomed Anal. 48(1): 171–76.

[20] Leikin J. B., Paloucek F. P., (2002) Poisoning & toxicology handbook, 3ª edição, Lexi-Comp, 712-71.



[23] Borges J.H.S., Souza A.H., Dória R. G.S., Canola J.C., Santos P.S.P., Valadão C.A.A. (2010); Efeitos da infusão contínua de ketamina S(+) em equinos anestesiados pelo halotano. 2010, Ci. Anim. Bras., Goiânia, v. 11, n. 1, p. 141-148,


[25] NIH. “Experimental Medication Kicks Depression in Hours Instead of Weeks” NIH News, 7 (2006).

[26] Mendes A.F. (2005); Fernandes F., S(+) cetamina em baixas doses: atualização / Low S(+) ketamine doses: a review.; Rev. bras. anestesiol; 55(4):460-469

[27] Tsen L.C. (2005)What’s new and novel in obstetric anesthesia? Contributions from the 2003 scientific literature.; International Journal of Obstetric Anesthesia, (14):2, 126-146

[28] ) Fatih Z., Serdar O., Ferruh B., Selcuk I., Ahmet C.,  (2010); Pain relief during dressing changes of major adult burns: Ideal analgesic combination with ketamine; Burns; (36):4, 501-505.


[30] Cottingham R, Thomson K.,  (1994); Use of ketamine in prolonged entrapment.; Journal of Accident & Emergency Medicine 11 (3): 189–91.

[31] Khamsi R. (2006); Ketamine relieves depression within hours, New Scientist.

[32] Zarate C.A., Singh J.B., Carlson P.J. (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression;  Archives of General Psychiatry 63 (8): 856–64

[33] Garcia L.S., Comim C.M., Valvassori S.S. (2008); Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus., Progress in Neuro-psychopharmacology & Biological Psychiatry 32 (1): 140–4.

[34]  Krupitsky E.M., Burakov A.M., Dunaevsky I.V., Romanova T.N., Slavina T.Y., Grinenko A.Y., (2007); Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence., Journal of Psychoactive Drugs 39 (1): 13–9.

[35] Rx -Correll GE, Futter GE (2006). “Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions”. Pain Medicine 7 (1): 92–5.

[36] Leeuw A.N.S., Forrester G.J., Spyvee P.D., Brash M.G.I.,  Delahay R.J. (2004); Experimental comparison of ketamine with a combination of ketamine butorphanol and medetomidine for general anaesthesia of the Eurasian badger; The Veterinary Journal, (167):2, 186-193.

[37] Vasconcelos S., Andrade M., Soares P., Gomes B. (2005); Aspectos gerais da cetamina e sua relação com esquizofrenia., Rev. psiquiatr. clín. v.32 n.1.

[38] Liebrenz M., Borgeat A., Leisinger R., Stohler R. (2007); Intravenous ketamine therapy in a patient with a treatment-resistant major depression. Swiss Medical Weekly 137 (15-16): 234–6.

[39] Report on the Risk Assessment of ketamine in the Framework of the Join Action on New Synthetic Drugs; EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION; Lisbon, 2000.

Índice de Tabelas

Tabela 1 –

Tabela 2 –

Índice de Figuras

Fig. 1 –

Fig. 2- e

Fig. 3-

Fig. 4- Adaptado de

Fig. 5-

Fig. 6-

Fig.7- adaptada de